Edwards Lifesciences Beats Q1 Estimates And Raises Full-Year Guidance

Edwards Lifesciences (NYSE:EW) reported first-quarter results that exceeded analyst expectations and raised its full-year outlook, sending shares 2% higher in pre-market trading today.

The company posted adjusted earnings per share of $0.78, surpassing the consensus estimate of $0.73 by $0.05. Revenue totaled $1.65 billion, exceeding the $1.6 billion estimate and rising 16.7% year-over-year, or 12.7% on a constant currency basis.

Edwards increased its fiscal 2026 constant currency sales growth guidance to a range of 9% to 11%, up from the prior range of 8% to 10%. It also raised its full-year adjusted EPS outlook to $2.95 to $3.05, from $2.90 to $3.05. The midpoint of $3.00 exceeded the analyst consensus estimate of $2.97.

For the second quarter of 2026, the company projected revenue between $1.66 billion and $1.74 billion, with a midpoint of $1.70 billion slightly above the $1.683 billion consensus. Adjusted EPS guidance for the quarter was set between $0.70 and $0.76, with the midpoint of $0.73 below the $0.75 analyst estimate.

About the Author
David Kirakosyan

Weekly Signals Desk analysis and API-driven market workflows

David Kirakosyan writes the Weekly Signals Desk for FMP, breaking down market signals while showing readers how to build similar workflows using the FMP API. His work focuses on turning raw API data into practical market analysis and repeatable workflows that developers and analysts can adapt to their own research.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account